Form 6-K Trillion Energy Internat For: May 15

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of May 15, 2026

 

Commission File Number: 000-55539

 

TRILLION ENERGY INTERNATIONAL INC.
(Translation of registrant’s name into English)

 

Suite 700, 838 West Hastings Street
Vancouver, BC, V6C 0A6
(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

☒ Form 20-F ☐ Form 40-F

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

 

 

 

On May 15, 2026, Trillion Energy International Inc. issued the news release filed herewith as Exhibit 99.1, providing a corporate update on its operations, private placement, annual filings, and MCTO status.

 

Exhibit No.
99.1		News Release May 15, 2026 – Trillion Provides Corporate Update

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

TRILLION ENERGY INTERNATIONAL INC.
/s/ David Thompson
David Thompson
Director, Audit Committee Chair
May 15, 2026

 

 

ATTACHMENTS / EXHIBITS

EX-99.1

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Best Crypto Presale 2026: Tesla-SpaceX Merger Talks Meet Remittix’s $33M Raise and November 24 Launch
• TAGRISSO® (osimertinib) plus savolitinib reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
• Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 S